Patent details

EP3866850 Title: COMBINATION THERAPY FOR MELANOMA

Basic Information

Publication number:
EP3866850
PCT Application Number:
US2019056923
Type:
European Patent Granted for LU
Legal Status:
In force
Application number:
EP197984644
PCT Publication Number:
WO2020081928
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
COMBINATION THERAPY FOR MELANOMA
French Title of Invention:
POLYTHÉRAPIE POUR MÉLANOME
German Title of Invention:
KOMBINATIONSTHERAPIE FÜR MELANOM
SPC Number:

Dates

Filing date:
18/10/2019
Grant date:
24/07/2024
EP Publication Date:
25/08/2021
PCT Publication Date:
23/04/2020
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
24/07/2024
EP B1 Publication Date:
24/07/2024
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
Expiration date:
18/10/2039
Renunciation date:
Revocation date:
Annulment date:

Owner

From:
17/07/2024
 
 

Name:
Bristol-Myers Squibb Company
Address:
Route 206 and Province Line Road, Princeton, NJ 08543, United States (US)

Agent

Name:
MARKS & CLERK LLP
From:
01/08/2024
Address:
BP 1775, 1017, LUXEMBOURG, Luxembourg (LU)
To:

Inventor

1

Name:
MAURER, Matthew
Address:
United States (US)

2

Name:
SIMONSEN, Katy L.
Address:
United States (US)

Priority

Priority Number:
201862748089 P
Priority Date:
19/10/2018
Priority Country:
United States (US)

Classification

IPC classification:
A61K 39/395; A61P 35/00;

Publication

European Patent Bulletin

Issue number:
202430
Publication date:
24/07/2024
Description:
Grant (B1)

Annual Fees

Annual Fee Due Date:
31/10/2025
Annual Fee Number:
7
Annual Fee Amount:
82 Euro
Expected Payer:
Last Annual Fee Payment Date:
09/09/2024
Last Annual Fee Paid Number:
6
Last Annual Fee Paid Amount:
66 Euro
Payer:
MARKS & CLERK LLP
Filing date Document type Number of pages
31/07/2024 Power Of Attorney 1
01/08/2024 Outgoing Correspondence 1